Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma

NCT00319865 is registered in ClinicalTrials.gov with Korean Multiple Myeloma Working Party as lead sponsor.

NCT NCT00319865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00319865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma
Lead sponsor
Korean Multiple Myeloma Working Party
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2005
Completion date
September 30, 2008
Enrollment
47
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma